5101
CD19
Relapsed/refractory non-Hodgkin lymphoma (rrNHL)
CAR-T
Our Pipeline
Focusing on high unmet medical needs, we synergize compelling science, technology, and collaborative approaches to create a deep pipeline of best-in-class small molecules, CAR-T therapies, and biologics in oncology and immunology.
Oncology
CAR-T
Program
Target
Indication
Modality
Preclinical
Phase 1
Phase 2
Phase 3
Approved
5201
CD19
Relapsed/refractory chronic lymphocytic leukemia and Richter transformation (rrCLL/RT)
CAR-T
5301
BCMA
Relapsed/refractory multiple myeloma (rrMM)
CAR-T
>5 programs
Multiple
Hematological oncology and solid tumors
CAR-T
>5 programs
Multiple
Solid tumors
Small molecule
Immunology
Small molecules
Program
Target
Indication
Modality
Preclinical
Phase 1
Phase 2
Phase 3
Approved
3667
TYK2
Systemic lupus erythematosus (SLE)
Small molecule
3667
TYK2
Dermatomyositis (DM)
Small molecule
>5 programs
Multiple
Inflammation/auto-immune
Small molecule
Visit our Clinical Trials Portal
Clinical trials are a critical part of our journey to evaluate investigational treatments and gain approval from health authorities such as the United States Food and Drug Administration (FDA) and the European Medicines Agency (EMA).
At Galapagos, we organize clinical trials in various therapeutic areas, conducting research that paves the way for innovative solutions.
Visit our Clinical Trials portal to explore the fascinating world of clinical trials. Discover how they’re set up and gain insight into what’s important when considering participation.
Our stories
More about our company, science and people
We curate a series of inspiring stories about how we are #LivingInnovation at Galapagos
Partnerships
Work with us!
We are adding new capabilities, technologies and product candidates through internal and external innovation. Let’s start #PioneeringForPatients, together!
Investor Hub
All information for investors…
… centralized in one Investor Hub. Discover how we aim to create value for all our stakeholders.